MedPath

A Study of Two Adherence Plans to Help HIV-Positive Patients Take Their Medications Correctly

Not Applicable
Completed
Conditions
HIV Infections
Registration Number
NCT00001129
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to look at different ways to help patients follow their anti-HIV medication schedules.

It is very important that HIV-positive patients take their anti-HIV medications correctly so they get the best possible benefit from them. Taking the drugs correctly, called "adherence," may keep HIV virus levels in the blood (viral load) low for a longer time. However, anti-HIV medication schedules are often complicated, and many patients have difficulty remembering to take their drugs at the correct time. This study will look at 2 different ways to teach patients about the importance of taking their medications correctly and to remind them when to take their medications.

Detailed Description

Adherence to antiretroviral (AR) therapy has become increasingly important in the management of HIV infection. Adherence to AR regimens is thought to be a critical factor in maintaining therapeutic drug levels, thus helping ensure viral suppression and minimizing the risk of drug resistance. However, AR regimens are often complex with demanding dosing schedules. Patients often miss doses because they simply forget; other factors such as substance abuse, depression, and low literacy levels also contribute to nonadherence. Adherence is influenced not only by individual behavior but also by the services, the quality of the patient-provider relationship, and the amount of social support offered the patient. There is no currently agreed upon, widely used, and generalizable intervention for improving adherence over the long course of HIV therapy. This study provides a long-term comparative evaluation of two interventions.

Clinical sites, rather than individual patients, are randomized to one of four groups: a medication manager, an electronic medication reminder system, a medication manager plus an electronic medication reminder system, or usual care. Special training sessions are held for the staff of participating units assigned to medication manager and/or electronic medication reminder system interventions. The medication manager is a research staff member who works individually with study patients, addressing the knowledge, motivation, and skills necessary for adherence. The electronic medication reminder system is ALR (A Little Reminder). This is a small, portable alarm that is programmed to sound and flash at the times of the patient's scheduled AR medication doses. Patients enrolling into either the FIRST or MDR-HIV study at clinical sites authorized to carry out this study are offered the option of participating in the adherence intervention to which the clinical site has been randomly assigned. Data collected through the FIRST and the MDR-HIV protocols are used to address the Adherence study objectives. Patients on the FIRST protocol are assessed for time to first plasma HIV-RNA level above 2,000 copies/ml. Also, patients on the FIRST and MDR-HIV studies are assessed for changes in viral load, resistance, CD4 cell counts, adherence, and other factors.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1248
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

AIDS Research Consortium of Atlanta

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

AIDS Research Alliance - Chicago

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Partners in Research / New Mexico

๐Ÿ‡บ๐Ÿ‡ธ

Albuquerque, New Mexico, United States

Bronx-Lebanon Hosp Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

Philadelphia FIGHT

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Richmond AIDS Consortium / Div of Infect Diseases

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

Community Consortium / UCSF

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Virginia Cafaro M.D.

๐Ÿ‡บ๐Ÿ‡ธ

San Francisco, California, United States

Univ TX Health Science Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

Univ Hosp Infectious Diseases Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Denver CPCRA / Denver Public Hlth

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Washington Reg AIDS Prog / Dept of Infect Dis

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Harlem AIDS Treatment Grp / Harlem Hosp Ctr

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

The Research and Education Group

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

North Jersey Community Research Initiative

๐Ÿ‡บ๐Ÿ‡ธ

Newark, New Jersey, United States

Henry Ford Hosp

๐Ÿ‡บ๐Ÿ‡ธ

Detroit, Michigan, United States

Yale Univ School of Medicine / AIDS Program

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

Wayne State Univ - WSU/DMC / Univ Hlth Ctr

๐Ÿ‡บ๐Ÿ‡ธ

Detroit, Michigan, United States

Southern New Jersey AIDS Clinical Trials

๐Ÿ‡บ๐Ÿ‡ธ

Camden, New Jersey, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath